Pharmaceutical composition containing a novel Nav1.7 monoclonal antibody
A monoclonal antibody targeting the E3 extracellular loop C-terminal region of Nav1.7 is developed to enhance pain and itching suppression by improving binding affinity and biological activity, addressing the limitations of existing antibodies.
JP2026120923APending Publication Date: 2026-07-23SHIONOGI & CO LTD
View PDF 10 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- SHIONOGI & CO LTD
- Filing Date
- 2023-04-28
- Publication Date
- 2026-07-23
AI Technical Summary
Technical Problem
Existing Nav1.7 monoclonal antibodies do not effectively bind to the E3 extracellular loop C-terminal region of domain C of Nav1.7 and demonstrate insufficient pain-suppressing and pruritic suppression effects.
Method used
Development of a monoclonal antibody with specific binding to the E3 extracellular loop C-terminal region of Nav1.7, incorporating variable regions with modified CDR sequences to enhance affinity and biological activity.
Benefits of technology
The monoclonal antibody effectively suppresses pain and itching by selectively inhibiting Nav1.7, demonstrating improved in vivo efficacy compared to previous antibodies.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026120923000016 
Figure 2026120923000017 
Figure 2026120923000018
Abstract
The object of the present invention is to provide a pharmaceutical composition containing a novel Nav1.7 monoclonal antibody. [Solution] Disclosed is a pharmaceutical composition comprising a Nav1.7 monoclonal antibody or an antibody fragment thereof having a specific CDR or a specific heavy chain variable region / light chain variable region. The pharmaceutical composition can be used for the treatment or prevention of pain, itching, etc.
Need to check novelty before this filing date? Find Prior Art